Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05516446
Other study ID # santemilitaire9
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 25, 2021
Est. completion date December 2022

Study information

Verified date August 2022
Source General Administration of Military Health, Tunisia
Contact Aymen Noamen, MD
Phone 0021620215773
Email no.aymen@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, open-label, single-center, non-inferiority clinical trial to compare late lumen loss (LLL) at 12 months in Tunisian population undergoing coronary percutaneous intervention between Drug Eluting Balloon treated group and Everolimus platinum chrome stent treated group.


Description:

Drug eluting stents (DES) leave a permanent metal implant that interferes with vasomotion, endothelial function and vascular remodeling. the rigid structure and the pharmacological properties of DES could overcome acute complications related to balloon dilation and late complications related to in-stent restenosis. However, they do not restore normal arterial function after the procedure. Drug eluting balloons (DEB) offer an alternative to the implantation of a durable material. They release a transient antiproliferative drug. They promise potential advantages over DES as: - an ad integrum restitution of the endothelium and its vasomotor properties. - a reduction of late thrombosis risk. - the possibility of grafting on the treated segment. - avoid the problems of side-branch trapped in the treatment of bifurcations. - improve the profitability of non-invasive imaging (coroscanner, magnetic resonance imaging) during patient follow-up. DEB is validated for the treatment of in-stent restenosis, especially focal and on small caliber arteries. The use of DEB in de novo lesions has been the subject of several studies. This therapeutic option should be evaluated in the Tunisian context The aim of this clinical trial is to compare the results of angioplasty by DEB (SEQUENT PLEASE) versus last generation DES: coronary stent system in platinum chromium alloy with everolimus elution (Promus Premier and Promus Elite) The Primary endpoint: late lumen loss at 12 months. The Secondary endpoint: the major cardiovascular event rate (MACE).


Recruitment information / eligibility

Status Recruiting
Enrollment 290
Est. completion date December 2022
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with silent ischemia, stable angina, unstable angina, or non-Q wave myocardial infarction. - a de Novo lesion on a never treated native artery. - A reference artery diameter between 2 mm and 4 mm. Non-inclusion criteria - Patients with STEMI in the acute phase or presenting a cardiogenic shock. - Patients with an allergy or a contraindication to double anti-platelet aggregation. - Pre-menopausal patients not using regularly an oral contraceptives or breast-feeding . - Patients with severe comorbidity or with an estimated survival of less than 12 months. - Dissected lesions or spontaneous dissections other than grade A or B requiring DES angioplasty. - In-stent restenosis. - Thrombotic lesions. Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DEB for de Novo Lesions
The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 µg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
DES for de Novo Lesions
The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)

Locations

Country Name City State
Tunisia Military hospital of Tunis Tunis

Sponsors (2)

Lead Sponsor Collaborator
General Administration of Military Health, Tunisia B. Braun Medical International Trading Company Ltd.

Country where clinical trial is conducted

Tunisia, 

References & Publications (1)

Zhong PY, Ma Y, Shang YS, Niu Y, Bai N, Wang ZL. Efficacy of Drug-Coated Balloon Approaches for de novo Coronary Artery Diseases: A Bayesian Network Meta-Analysis. Front Cardiovasc Med. 2022 Jun 21;9:899701. doi: 10.3389/fcvm.2022.899701. eCollection 2022. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary late lumen loss (LLL) late lumen loss between Drug Eluting Balloon treated group and Drug Eluting Stents treated group evaluated by quantitative coronary analysis Follow-up coronary angiography at 12 months after the percutaneous coronary intervention
Secondary rate of major adverse cardiac events (MACE) Major adverse cardiac event defined as the composite of myocardial infarction, target vessel revascularization and cardiac death 6 months and 12 months after percutaneous coronary intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT01435031 - EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions N/A
Terminated NCT01443754 - Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease N/A
Completed NCT00783302 - Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care N/A
Completed NCT00543400 - Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Phase 2
Completed NCT05516784 - Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile Phase 4
Completed NCT02873052 - MyoVista Measurements in Patients With Atherosclerosis and CAD
Terminated NCT02984891 - Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
Completed NCT05292144 - Xperience Pro PMCF Study
Completed NCT02554292 - Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
Active, not recruiting NCT06052319 - A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
Completed NCT00265525 - Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease. Phase 3
Completed NCT03570697 - Imaging of Coronary Plaques in Participants Treated With Evolocumab Phase 3
Terminated NCT05508893 - Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT) N/A
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Completed NCT02098772 - Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol Phase 3